VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LXRXLexicon Pharmaceuticals, Inc.
$2.55$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLXRXCash Flow

Lexicon Pharmaceuticals, Inc. (LXRX) Cash Flow Statement

27Y historyFree accessUpdated daily

Free cash flow remains deeply negative, with a $14.7M outflow in 2026Q1, highlighting a structural inability to fund commercialization through internal product sales.

LXRX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Cash from Operations-38.8M-67.85M-178.78M-161.9M-88.85M-87.02M-142.97M113.81M-148.61M-185.39M-175.63M184.78M-75.62M-91.08M-94.46M-87.94M-82.37M-89.02M-95.6M-74.32M-56.91M23.44M-42.26M-7.72M-28.79M-17.99M-1.5M-9.6M
Operating CF Margin %--136.24%-575.21%-13446.59%-63921.58%-29200.34%-595.83%35.34%-235.1%-205.23%-210.74%142.12%-330.89%-4098.96%-8674.01%-4755.98%-1678.24%-831.93%-295.78%-148.3%-78.17%30.98%-68.44%-18.01%-81.8%-5.89%-10.38%-204.26%
Operating CF Growth %276.73%62.05%-10.43%-82.21%-2.11%39.14%-225.62%176.58%19.84%-5.56%-195.05%344.34%16.97%3.58%-7.42%-6.76%7.47%6.89%-28.63%-30.6%-342.77%155.48%-447.64%73.2%-60.04%-1098.14%84.36%-
Net Income-26.09M-50.34M-200.4M-177.12M-101.94M-87.76M-58.57M130.13M-120.55M-129.05M-141.43M-4.68M-100.29M-104.13M-110.21M-116.22M-101.78M-93.32M-76.86M-58.79M-54.31M-36.31M-47.17M-64.2M-59.67M-35.17M-25.99M-12.5M
Depreciation & Amortization555K621K534K554K427K292K2.93M3.65M3.68M3.4M2.06M727K1.93M2.86M4.19M4.89M5.39M6.16M10.07M10.42M11.2M11.63M12.87M21.53M20.58M16.55M2.62M2M
Stock-Based Compensation6.03M12.52M13.5M14.34M11.52M10.58M13.27M14.22M11.7M9.47M7.45M6.84M7.08M7.42M6.5M5.71M5.48M5.27M6.5M7.93M7.03M0000000
Deferred Taxes0000049K-110K-6.01M0-12.66M16K3.55M-70K00116.92M4.82M2.58M-26.52M-20.36M-7M0000000
Other Non-Cash Items4.77M-3.75M-6.65M-2.33M744K54K-131.57M30.1M1.34M2.7M-176K6.45M13.44M-2.21M9.89M-109.45M2.71M-1.17M7.81M7.93M7.03M10K-11K3.06M197K020.84M0
Working Capital Changes-24.07M-26.89M14.24M2.66M402K-10.23M31.08M-58.29M-44.77M-59.26M-43.55M171.89M2.29M4.97M-4.82M10.21M1.01M-8.54M-16.6M-21.44M-20.86M48.11M-7.95M31.89M10.1M632K1.03M900K
Change in Receivables-9.33M1.09M-2.46M-982K-14K381K53.23M-50.61M-1.1M166K-4.08M124K457K588K-1.03M0000000000000
Change in Inventory-75K-50K150K-381K00345K437K-2.73M-1.95M6.23M-5.79M-128K1.7M-2.5M0000000000000
Change in Payables-15.43M-30.22M14.8M6.45M76K-14.16M-20.97M20.1M-18.86M-7.17M27.65M6.2M1.27M3.12M-995K10.37M-5.24M-2.79M-2.26M2.62M1.68M0000000
Cash from Investing2.17M113.02M-15.38M-49.94M-71.08M2.11M380.76M-155.85M169.58M50.52M18.25M-117.02M-108.42M99.54M-97.81M69.95M-113.84M11.88M159.41M-187.95M24.46M-15.99M40.48M-128K47.23M6.42M-165.45M5.2M
Capital Expenditures00-1.03M-470K-1.33M-1.22M-87K-70K-95K-228K-231K-910K-80K-1.72M-492K-1.21M-1.13M-369K-2.19M-1.9M-3.58M-11.28M-11.81M-4.82M-19.77M-13.47M-7.71M-4.1M
CapEx % of Revenue0%-3.32%39.04%953.96%409.73%0.36%0.02%0.15%0.25%0.28%0.7%0.35%77.45%45.18%65.22%23.06%3.45%6.77%3.79%4.92%14.91%19.13%11.26%56.15%4.41%53.32%87.23%
Acquisitions000069.75M-3.33M11.01M155.78M000335K0000-5.56M0-20.06M00091K48K0000
Investments----------------------------
Other Investing1.65M3.71M9.3M0-69.75M3.33M160.38M-155.78M169.67M50.75M18.48M335K2.17M130K85K2.63M64K107K20.06M1K56K123K14.37M-27.48M-22.79M-752K00
Cash from Financing40.83M-48.5M238.35M187.96M142.21M22.71M-147.64M-2.23M-2.24M149.93M987K-2.03M283.81M-1.39M36.38M157.08M142.87M91.82M-880K254.99M40.7M-95K-19.47M50.4M4.57M-3.19M202.73M3.4M
Debt Issued (Net)-53M-48M049.96M48.87M-11.7M-216.58M-1.28M-2M143.63M-2.02M-1.86M82.42M-1.57M-1.44M-3.59M-38.48M36.47M-881K-815K-751K-691K-18.71M04M-3.91M-1.59M3.5M
Equity Issued (Net)96.67M73K239.59M138M-864K34.41M-1.03M-941K-240K6.31M3M-243K201.38M211K37.82M160.67M181.35M55.35M1K213.09M41.45M596K1.71M50.4M574K718K204.33M0
Dividends Paid0000000000000000000000000000
Share Repurchases00-1.73M-824K-864K-2.67M-1.03M-941K-972K-1.68M-621K-357K-887K-873K-285K-108K-149K-88K0000000000
Other Financing-2.84M-572K-1.24M094.2M069.97M000070K0-26K0000042.71M00-2.47M00000
Net Change in Cash4.2M-3.33M44.19M-23.88M-17.72M-62.2M90.15M-44.27M18.73M15.06M-156.39M65.72M99.77M7.08M-155.89M139.1M-53.35M14.68M62.94M-7.29M8.26M7.36M-21.24M42.55M23.01M-14.76M35.79M-1M
Free Cash Flow-38.8M-67.85M-179.81M-162.37M-90.18M-88.24M-143.06M113.74M-148.7M-185.62M-175.86M183.87M-75.7M-92.8M-94.95M-89.14M-83.5M-89.39M-97.79M-76.22M-60.49M12.16M-54.07M-12.54M-48.56M-31.46M-9.21M-13.7M
FCF Margin %-55.72%-136.24%-578.52%-13485.63%-64875.54%-29610.07%-596.19%35.31%-235.25%-205.48%-211.02%141.42%-331.24%-4176.42%-8719.19%-4821.2%-1701.3%-835.37%-302.55%-152.09%-83.09%16.07%-87.57%-29.27%-137.95%-10.3%-63.71%-291.49%
FCF Growth %76.97%62.27%-10.74%-80.05%-2.2%38.32%-225.78%176.49%19.89%-5.55%-195.65%342.88%18.42%2.27%-6.52%-6.76%6.58%8.59%-28.29%-26.01%-597.39%122.49%-331.16%74.18%-54.34%-241.56%32.77%-
FCF per Share-0.10-0.19-0.56-0.73-0.54-0.61-1.290.97-1.41-1.76-1.691.77-0.99-1.27-1.36-1.83-1.93-4.30-5.00-5.35-6.331.33-5.98-1.54-6.50-4.39-1.55-3.91
FCF Conversion (FCF/Net Income)1.49x1.35x0.89x0.91x0.87x0.99x2.44x0.87x1.23x1.44x1.24x-39.47x0.75x0.87x0.86x0.76x0.81x1.08x1.24x1.26x1.05x-0.65x0.90x0.12x0.48x0.51x0.06x0.77x
Interest Paid00000000000000002.42M2.52M0000000000
Taxes Paid000000000000000026K102K0000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity shortfall risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Remains Highly Volatile

According to quarterly financial disclosures, the relationship between net income and operating cash flow is erratic, with OCF/NI ratios swinging from 1.11 to over 14.00, indicating that reported earnings provide little insight into the actual cash-generating capacity of the underlying commercial operations.

The extreme variance in the OCF/NI ratio suggests that non-cash items and significant working capital swings are distorting the company's bottom line. Investors should interpret these fluctuations as a sign that the business has yet to establish a stable, predictable link between accounting profitability and cash realization.

Persistent Free Cash Flow Deficits

As reported in recent SEC filings, Lexicon's free cash flow trajectory remains deeply negative, with quarterly outflows frequently exceeding $20 million, highlighting a structural inability to fund commercialization efforts through internal product sales rather than external capital infusions.

The consistent failure to generate positive free cash flow suggests that the current commercial launch of INPEFA is not yet self-sustaining. This trajectory implies that the company remains entirely dependent on external financing to bridge the gap between high operating expenses and insufficient product-driven cash inflows.

Working Capital Swings Obscure Performance

Based on the provided cash flow statements, working capital changes are highly unstable, with quarterly fluctuations ranging from a $16.4 million outflow to an $11.2 million inflow, suggesting that inventory and accounts receivable management are currently volatile components of the company's cash position.

These erratic working capital movements may indicate inconsistent collection cycles or lumpy inventory stocking patterns associated with the early stages of the INPEFA launch. Such volatility warrants further investigation into whether these shifts represent genuine operational efficiency or merely temporary timing differences in revenue recognition.

Stock-Based Compensation Masks Cash Reality

Data from recent financial statements reveals that stock-based compensation, which reached as high as $4.9 million in a single quarter, serves as a significant non-cash adjustment that effectively masks the true magnitude of the company's ongoing cash burn and operational inefficiency.

By relying on equity-based incentives to manage compensation, the company avoids immediate cash outflows but creates a persistent dilution risk for shareholders. This practice suggests that the reported cash flow figures may be slightly flattered, potentially understating the true economic cost of maintaining the current workforce.

LXRX — Frequently Asked Questions

Quick answers to the most common questions about buying LXRX stock.

How much cash does Lexicon Pharmaceuticals, Inc. (LXRX) generate from operations?

Lexicon Pharmaceuticals, Inc. (LXRX) generated $-67.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Lexicon Pharmaceuticals, Inc.'s free cash flow?

Lexicon Pharmaceuticals, Inc. (LXRX) reported negative free cash flow of $67.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Lexicon Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Lexicon Pharmaceuticals, Inc. (LXRX) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.